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Abstract
Background: Motor neuron loss is characteristic of cervical spinal cord injury (SCI) and contributes to functional deficit.
Methodology/Principal Findings: In order to investigate the amenability of the injured adult spinal cord to motor neuron
differentiation, we transplanted spinal cord injured animals with a high purity population of human motor neuron
progenitors (hMNP) derived from human embryonic stem cells (hESCs). In vitro, hMNPs displayed characteristic motor
neuron-specific markers, a typical electrophysiological profile, functionally innervated human or rodent muscle, and
secreted physiologically active growth factors that caused neurite branching and neuronal survival. hMNP transplantation
into cervical SCI sites in adult rats resulted in suppression of intracellular signaling pathways associated with SCI
pathogenesis, which correlated with greater endogenous neuronal survival and neurite branching. These neurotrophic
effects were accompanied by significantly enhanced performance on all parameters of the balance beam task, as compared
to controls. Interestingly, hMNP transplantation resulted in survival, differentiation, and site-specific integration of hMNPs
distal to the SCI site within ventral horns, but hMNPs near the SCI site reverted to a neuronal progenitor state, suggesting an
environmental deficiency for neuronal maturation associated with SCI.
Conclusions/Significance: These findings underscore the barriers imposed on neuronal differentiation of transplanted cells
by the gliogenic nature of the injured spinal cord, and the physiological relevance of transplant-derived neurotrophic
support to functional recovery.
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Introduction
Cell based strategies for central nervous system (CNS) repair are
inherently combinatorial in nature, in that they replace dead or
dying cells, provide a substrate for endogenous neural growth and
angiogenesis, and provide neurotrophic support for the endoge-
nous environment. The contribution of a cell type’s phenotypic or
neurotrophic benefit to functional recovery has historically been
difficult to distinguish, as the heterogeneous population of cells
within most transplants yields multiple cellular phenotypes and
neurotrophic secretions post-transplantation.
Neurotrophic secretions characterize all progenitor cells and are
known to alter injury and disease pathogenesis. For example,
human neural stem cells constitutively secrete nerve growth factor
(NGF), brain-derived neurotrophic factor (BDNF), and glial-
derived neurotrophic factor (GDNF) that promote growth of
injured axons following spinal cord injury [1]. Human embryonic
germ cell-derived embryoid bodies secrete BDNF and transform-
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reafferentation of host motor neurons when transplanted into rats
with diffuse motor neuron paralysis [2]. In addition, oligodendro-
cyte progenitors differentiated from hESCs express hepatocyte
growth factor (HGF), Activin A, transforming growth factor b-2
(TGF-b2) and BDNF [3], which may contribute to recovery of
function following SCI [4,5]. Thus, transplanted stem cell
derivates can influence the injured environment by providing
survival factors, guidance molecules, or cues for proliferation and
differentiation of endogenous stem and progenitor cells.
Likewise, the differentiation of transplanted cells is dictated by
the environmental signals and cellular deficiencies operating at the
site of implantation. Transplantation of multipotent spinal cord
progenitor cells into the uninjured spinal cord results in glial
differentiation [6,7], while transplantation into neurogenic regions
of the brain results in neuronal differentiation [6]. Within the
injured spinal cord, the innate gliogenic repair mechanisms
enhance glial differentiation of transplanted multipotent cells.
This is evidenced by multiple studies demonstrating glial
differentiation of neural stem cells [8], adult spinal cord progenitor
cells [7,9,10] and human embryonic stem cell-derived oligoden-
drocyte progenitor cells [5] following transplantation into injured
spinal cords. Indeed, neuron-restricted precursor cells can
differentiate into mature neuronal subtypes when transplanted
into adult non-injured spinal cord, but retain an immature state
when transplanted into injured spinal cord [11].
In order to investigate the reciprocal interaction between the
injured spinal cord and a motor neuron progenitor transplant
population, we treated spinal cord injured animals with a high
purity population of hMNPs. Our data underscore the gliogenic
nature of the injured adult spinal cord, and the physiological
relevance of transplant-derived neurotrophic factor release.
Results
Summary of Experimental Design
hESCs were differentiated into high purity populations of
hMNPs. The phenotype of the resulting cell population was
confirmed by analyses of morphology, immunocytochemical
marker expression, kainate-stimulated uptake of Co
2+ ions by
Ca
2+ permeable AMPA channels, electrophysiology, glutamate-
mediated excitotoxicity, and hMNP-muscle co-cultures. To
investigate the neurotrophic potential of hMNP secretions in vitro,
we performed growth factor expression analyses, followed by
functional assays of hMNP secretions on cortical neurons to assess
neurite branching, axonal regeneration and survival of cortical
neurons in a neurotoxic environment. The neurotrophic activity of
hMNP secretions was confirmed by exposing cortical neurons to
hMNP-CM pre-incubated with function blocking antibodies to
hMNP-secreted growth factors. The survival, differentiation, and
site-specific integration of hMNPs transplanted in the ventral
horns cranial and caudal to bilateral cervical contusion injuries
was investigated at distances from the injury sites, to investigate the
reciprocal interaction between the injured spinal cord and a
neuronal transplant population. A rodent model of motor neuron
loss was also transplanted with hMNPs, to ensure that the
differentiation profile in spinal cord injured animals was a result of
the injured spinal cord rather than an inherent property of the
transplant population. To investigate the neurotrophic potential of
hMNP secretions in vivo, we assayed transplanted animals for
sprouting of endogenous fiber tracts, sparing of endogenous
neurons, gross tissue sparing, suppression of intracellular signal-
ing pathways associated with SCI pathogenesis, and functional
ability.
hMNP Differentiation
At day 7 of the 28 day differentiation protocol, 47.8+/218.2%
of cells expressed the undifferentiated hESC marker OCT4,
42.5+/213% of cells expressed the early neural progenitor marker
Pax6, 38.3+/212.1% of cells expressed the early neural pro-
genitor marker nestin, 4.8+/22% of cells expressed the mesoder-
mal marker SMA, and 0.5+/21.3% of cells expressed the
mesodermal marker aFP. Cultures consisted of solid core 100–
600 mm spheres (Fig. 1a), and single cells were eliminated by daily
feeding. After plating at day 21, hMNPs migrated radially from
neurospheres.
At day 25, cells exhibited processes (Fig. 1b) and 99. 2+/20.6%
of cells expressed the MNP marker Olig1/2 (Fig. 1c), 99.2+/
20.44% of cells expressed the MNP marker Isl-1, 98.8+/21.3%
of cells expressed the neuronal marker Tuj1 (Fig. 1d, green). Less
than 1% of cells expressed the astrocyte marker GFAP (Fig. 1d,
red), 5.5%+/23.6% of cells expressed the MN marker HB9, and
no cells expressed the mature MN marker ChAT. Less than 0.1%
remained unlabeled.
At day 28, the day of transplantation, 96.7+/22.62% of cells
expressed the MN marker HB9 (Fig. 1e). Similar to the day 21
immunocytochemical profile, less than 1% of cells expressed the
astrocyte marker GFAP and no cells expressed the mature MN
marker ChAT. No Oct4 positive stem cells could be identified on
or after day 28.
To assess maturation in vitro, hMNPs were plated on astrocytes
and allowed to mature for 3 weeks. Matured hMNPs displayed a
mature, branched morphology (Fig. 1f), 97.7+/21.53% of cells
expressed the mature neurofilament marker SMI-32 (Fig. 1g), and
96.6+/24.4% of cells expressed the MN marker ChAT (Fig. 1h),
while Olig 1/2 and HB9 expression decreased significantly
(p,0.001; 2+/21.3% and 6+/24.4%, respectively). SMI-32
positive cells exhibited distinct morphological features of mature
MNs, including a large cell body size (.25 mm), a well-developed
dendritic tree, and a distinct axon. MN maturation was further
demonstrated by kainate-stimulated uptake of Co
2+ ions by Ca
2+
permeable AMPA channels. Less than 1% of anti-human nuclear
positive cells displayed GFAP+ immunoreactivity, and no SMI-32,
or ChAT immunoreactive cells were GFAP+. Less than 0.1%
remained unlabeled.
MN Functionality
The functionality of hMNPs was assessed by electrophysiology,
glutamate-mediated excitotoxicity, and hMNP-muscle co-culture
experiments. hMNPs matured for 8 weeks consistently displayed
resting potentials of 240 to 260 mV. Injection of 20pA to MNs
current clamped in the whole cell configuration (Fig. 2a) elicited
trains of action potentials, typical of mature MNs (Fig. 2b). The
presence of glutamate receptors was evidenced using symmetrical
solutions such that at 0 mV, the addition of 100 mM glutamate
mediated a small outward current, likely due to the presence of
KOH in the internal solution (Fig. 2c), and at 270 mV the
addition of glutamate mediated a large inward current, as K
+ and
Ca
2+ ions flowed through open glutamate receptors (Fig. 2d).
Exposure of hMNPs to glutamic acid at increasing concentra-
tions resulted in increasing amounts of hMNP death. The
percentage of propidium iodide (PI) positive cells was 11.36+/
21.25% for 0 mM glutamic acid, 9.68+/22.2% for 500 mM
glutamic acid, and 17.47+/21.3% for 2000 mM glutamic acid.
The percentage of Annexin V positive cells was not significantly
different (p.0.01) than the percentage of PI positive cells.
Separation of MN and muscle cell bodies in microfluidic culture
platforms connected by 5–20 mm micro-channels [12] was
required for stable functional innervation of myotubes. hMNPs
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an increase in dendritic arborization, and extension of neurites
through the micro-channels into the other chamber. Approxi-
mately 40% of the myoblasts fused to form myotubes, which
displayed spontaneous contractile activity upon innervation with
MN neurites. After innervation, a-bungarotoxin, synaptophysin
and ChAT staining was significantly (p,0.001) increased over
myotube cultures that lacked innervation. No spontaneous
contractile activity, a-bungarotoxin, synaptophysin and ChAT
staining could be detected in this system when no hMNPs were
seeded.
hMNPs Secrete Physiologically Active Growth Factors
To investigate theneurotrophicpotentialof hMNP secretions, we
performed growth factor expression analyses,followed byfunctional
assays of hMNP secretions on cortical neurons in vitro. PCR (Fig. 3a)
and Western blot analyses (Fig. S1b) indicated that hMNPs both
express and secrete neurotrophin-3 (NT-3), neurotrophin-4 (NT-4),
Figure 1. Morphological and immunocytochemical characterization of hMNPs at different stages of differentiation. (a) At day 7 of the
28 day protocol, cultures contained yellow solid core neurospheres in the absence of single floating cells. (b) At day 25, morphologically
homogeneous cells exhibited processes, and (c) expressed the MN lineage marker Olig 1/2 (red), and (d) Tuj1 (green); GFAP+ astrocytes (red) were
rare within these Tuj1+ cultures. Nuclear counterstain for (c) and (d) is blue. (e) At day 28, the majority of Tuj1+ cells (green) double stained for the MN
lineage marker HB9 (red). (f) After 3 weeks of subsequent growth, cells displayed a mature, branched morphology consistent with mature MNs, and
expressed the mature MN markers (g) SMI-32 and (h) ChAT. Bar=1000 mm for (a), 200 mm for (b) and (g), 100 mm for (c) and (d), 50 mm for (e), 33 mm
for (f), and 150 mm for (h).
doi:10.1371/journal.pone.0011852.g001
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growth factor (VEGF). Further analysis using real-time PCR
revealed a 10-fold increase in NT-3, a 23-fold increase in NT-4,
an 18-fold increase in VEGF, a 3.5-fold increase in CNTF (ciliary
neurotrophicfactor),a6-foldincreaseinIL10,a121-foldincreasein
NRG4 (neuregulin 4), and a 275-fold increase in NPY (neuropep-
tide Y) when compared to hFib controls. Interestingly, there was a
5-fold decrease in NGF expression in hMNP when compared to
hFibs (Fig. S1a). PCR analyses indicated that TGFa, BDNF and
GDNF were not produced by the hMNPs.
Neurite length was 58% longer (Fig. 3b) in cortical neuron
cultures exposed to hMNP-CM for 7 days (Fig. 3c) as compared to
cortical neuron cultures exposed to MN differentiation media
(Fig. 3d; 182+/215 mm and 115+/211 mm, respectively;
p,0.001). The neurofilament optical density was 45% greater
(Fig. 3e) in the axonal chamber of microfluidic culture platforms in
axotomized cortical neuron cultures exposed to hMNP-CM for 7
days (Fig. 3f) as compared to axotomized cortical neuron cultures
exposed to MN differentiation media (Fig. 3g; 15.5+/22.2 mm
and 10.7+/21.8 mm, respectively; p,0.001). MAP-2 immuno-
staining of the two chamber microfluidic culture platforms
confirmed that no cells migrated to the axonal chamber.
The neurotrophic activity of hMNP secretions was confirmed
by exposing cortical neurons to hMNP-CM pre-incubated with
function blocking antibodies to hMNP-secreted growth factors.
Neurite length was significantly attenuated in cortical neuron
cultures exposed to hMNP-CM that contained function-blocking
antibodies to hMNP-secreted growth factors (Fig. 3h); average
neurite length decreased from 185+/210 mm to 135+/29 mmi n
the presence of anti-NT3 (p,0.01), 138+/28 mm in the presence
of anti-NT4 (p,0.01), 149+/28 mm in the presence of anti-NGF
(p,0.01), and 119+/26 mm in the presence of anti-VEGF
(p,0.01). There was no significant difference (p.0.01) in neurite
length of cortical neurons cultured in the presence of hMNP-CM
containing function-blocking antibodies to GDNF, which is not
detected in hMNPs (156+/210 mm). In addition, there was no
significant difference (p.0.01) in average neurite length of cortical
neurons cultured in the presence of MN differentiation media
(115+/211 mm) and cortical neurons cultured in the presence of
MN differentiation media containing function-blocking antibodies
to NT3 (99+/27 mm), NT4 (101+/29 mm), NGF (133+/
217 mm), VEGF (102+/26 mm), and GDNF (142+/29 mm).
To investigate the effects of hMNP-CM on neuronal survival in
a neurotoxic environment, cortical neurons were exposed to
Figure 2. Electrophysiological profile of hESC-derived MNs. (a) Electrophysiological activity was assessed in MNs current clamped in the
whole cell configuration. (b) Injection of 20 pA of current elicited action potential trains, typical of mature MNs. The presence of glutamate receptors
was evidenced using symmetrical solutions. (c) At 0 mV, the addition of glutamate mediated a small outward current, likely due to the presence of
KOH in the internal solution. (d) At 270 mV, the addition of glutamate mediated a large inward current, as K
+ and Ca
2+ ions flowed through open
glutamate receptors. Bar=33 mm.
doi:10.1371/journal.pone.0011852.g002
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PLoS ONE | www.plosone.org 4 July 2010 | Volume 5 | Issue 7 | e11852Figure 3. hMNPs secreted physiologically active growth factors. (a) QualitativePCRanalysesindicatedthathMNPsexpressNT-3,NT-4,NGF,and
VEGF.Neuritelengthwas58%longer(b)incorticalneuronculturesexposedtohMNP-CMfor7days(c)ascomparedtocorticalneuronculturesexposedto
MNdifferentiation media(d).The neurofilament optical densitywas 45% greater (e) in the axonalchamber ofmicrofluidic culture platforms in axotomized
cortical neuron cultures exposed to hMNP-CM for 7 days (f) as compared to axotomized cortical neuron cultures exposed to MN differentiation media (g).
(h) Neurite length was significantly attenuated in cortical neuron cultures exposed to hMNP-CM that contained function-blocking antibodies to MN
growthfactors.Immunofluorescent stainingforMAP-2 inculturesexposedtocontrol media (i) orhMNP-CM (j), inthe presenceofLPS.(k) Quantification of
the number of MAP-2 positive neurons in the presence of control media or hMNP-CM, withand without LPS exposure. The number of neurons in cultures
lacking LPS wasnot significantlydifferent(p,0.05) incultures exposedtocontrolmediaorMNP CM,however,thenumberofneurons incultures withLPS
was significantly higher (p,0.05) in cultures exposed to hMNP-CM as compared to those exposed to control media. Bar=50 mm.
doi:10.1371/journal.pone.0011852.g003
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microglial conditioned media (LPS MG-CM), in the presence of
hMNP-CM or motor neuron differentiation media. Immunoflu-
orescent staining for MAP-2 in cultures exposed to control media
(Fig. 3i) or hMNP-CM (Fig. 3j) in the presence of MG-CM,
indicated that the number of MAP-2 positive neurons in cultures
without LPS activation was not significantly different (p,0.05). In
cultures exposed to LPS MG-CM, however, the number of
neurons was significantly higher (p,0.05) in the presence of
hMNP-CM as compared to control media (Fig. 3k). These findings
demonstrate that hMNPs secrete physiologically active growth
factors which promote neuronal survival in an inflammatory
environment and enhance axonal sprouting and regeneration in
vitro.
Localization and Differentiation of hMNPs in a SCI Model
To investigate the reciprocal interaction between the injured
spinal cord and a neuronal transplant population, the survival,
differentiation, and site-specific integration of hMNPs was
investigated at distances from SCI sites, following transplantation
of hMNPs cranial and caudal to bilateral contusion injuries.
Human nuclear antigen-positive cells were detected in all
transplanted animals, and did not migrate from the transplant
sites cranial and caudal to the injury epicenter. Human cells
(Fig. 4a) within the ventral horns double stained with Isl-1 (Fig. 4b),
p75 (Fig. 4c; p75 in red, human nuclei in green), neurofilament or
ChAT (Fig. 4d; ChAT in blue, human nuclei in brown), consistent
with a MN lineage of mixed maturation state. Some human cells
in the ventral horns were surrounded by synaptophysin positive
processes, suggesting integration with host tissue (Fig. 4e; synapto-
physin in red, human nuclei in green). Many human nuclear
antigen-positive cells extended Tuj1 positive processes, and in
some animals, ectopic motor tracts were present in the dorsal and
ventral white matter (Fig. 4f; Tuj1 in red, human nuclei in green).
Tuj1 positive structures had an irregular trajectory and included
varicosities along their length, characteristic of new axon growth
[13]. No-primary and no-secondary antibody controls yielded no
Tuj1 tissue staining. None of the CTB+ MNs retrogradely labeled
following CTB injection into peripheral muscle contained a
human nucleus, demonstrating that transplanted cells did not
extend axons into the periphery or form neuromuscular junctions
with host tissue, as expected.
Although most transplanted cells were located in the parenchy-
ma cranial and caudal to the injury epicenter where they were
placed, transplanted cells were found within the injury epicenter in
5 out of 15 animals. These human cells outside of the ventral horns
were predominantly nestin positive or double cortin positive,
suggesting back-differentiation to an early neuronal phenotype,
and some were GFAP positive suggesting amplification of the
minor astrocyte population within the transplant. No human
nuclear antigen-positive cells expressed markers for oligodendro-
cytes.
Localization and Differentiation of hMNPs in a Motor
Neuron Loss Model
The Smn
2/2;SMND7
+/+;SMN2
+/+ model of motor neuron loss
was also transplanted with hMNPs, to ensure that the differen-
tiation profile in spinal cord injured animals was a result of the
injured spinal cord rather than an inherent property of the
transplant population. As these mutants have a shortened lifespan,
animals were sacrificed within 13 days of transplantation; the
lifespan of this animal model limits the time available for
differentiation of transplanted cells. Human cells were detected
in all Smn
2/2;SMND7
+/+;SMN2
+/+ mice in the ventral horns of the
spinal cord. All human nuclear antigen-positive cells double
stained with Isl-1, confirming the MN differentiation potential of
the transplant population in a model of MN loss that lacks a spinal
cord injury. Isl-1 staining was absent in non-transplanted animals,
consistent with their MN pathology. Human nuclear antigen-
positive cells did not double label with markers for the mature
motor neuron markers ChAT or SMI-32, indicating that 13 days
of survival in vivo was insufficient for differentiation of trans-
planted hMNPs. Importantly, very few of the human-positive cells
were nestin, double-cortin, or GFAP positive, indicating that the
abundance of these cells in SCI sites was a result of the SCI
environment rather than the default differentiation profile of the
transplant population.
Transplantation of hMNPs Caused Histological Benefit
To investigate the neurotrophic potential of hMNP secretions in
vivo, we assayed transplanted animals for sprouting of endogenous
fiber tracts, sparing of endogenous neurons, gross tissue sparing,
and suppression of intracellular signaling pathways associated with
SCI pathogenesis.
hMNP transplantation enhanced sprouting of endogenous
serotonergic (5-HT) projections (Fig. 5a, b). In vehicle-injected
animals, the patterning of serotonergic projections was consistent
with that documented in the literature; there was high innervation
of laminae I and II, some diffuse labeling in lamina V, and highly
distributed innervation throughout the ventral horn (Fig. 5a). The
amount of 5-HT immunoreactivity was lowest at 3 mm cranial to
the injury epicenter (961) but progressively increased up to 1 mm
cranial to the injury epicenter (1463, Fig. 5b). Immediately caudal
to the injury epicenter, the labeling of serotonergic projections
decreased again (961) followed by a slight increase up to 3 mm
caudal to the injury epicenter (1262, Fig. 5b). In contrast, hMNP-
transplanted animals consistently contained a higher degree of 5-
HT immunoreactivity in regions corresponding to the location of
transplanted cells. hMNP-transplanted animals consistently con-
tained aberrant projections throughout the deeper laminae of the
dorsal horn and dense innervation of the ventral horns (Fig. 5a,
arrows). At 2 mm and 3 mm cranial to the injury epicenter, and
1 mm caudal to the injury epicenter, 5-HT immunoreactivity was
significantly greater than that observed in vehicle-injected animals
(1762 vs. 1261, p,0.05; 1861 vs. 961, p,0.001; 1461 vs. 961,
p,0.05, respectively). At 1 mm cranial to the injury epicenter, and
2 mm and 3 mm caudal to the injury epicenter, 5-HT
immunoreactivity was not significantly different than in vehicle-
injected animals (p.0.5).
hMNP transplantation enhanced survival of endogenous
neurons (Fig. 5c, d). Serial sections were labeled for human nuclei
to ensure no human neurons were included in the NeuN cell
counts. Cranial to the injury epicenter, vehicle-injected animals
had an average of 865680 endogenous neurons whereas hMNP-
transplanted animals had an average of 1091651 endogenous
neurons (p,0.05). Caudal to the injury epicenter, vehicle-injected
animals had an average of 871651 endogenous neurons whereas
hMNP-transplanted animals had an average of 1098657
endogenous neurons (p,0.01).
hMNP transplantation enhanced gross tissue sparing. Morpho-
metric analyses revealed a significantly greater amount of spared
tissue in hMNP-transplanted animals compared to vehicle
controls, both rostral (7.460.5 mm
2 versus 5.4460.58 mm
2) and
caudal (8.1360.6 mm
2 versus 5.6760.34 mm
2) to the injury
epicenter. There was no significant difference in tissue sparing
between hMNP-transplanted and hFib-transplanted animals. This
latter finding indicates that increases in neuronal survival,
serotonergic innervation and functional recovery (see below)
Motor Neuron Transplant
PLoS ONE | www.plosone.org 6 July 2010 | Volume 5 | Issue 7 | e11852observed in hMNP-transplanted animals were not due to tissue
sparing, as they were absent in hFib-transplanted animals (Fig. 6).
This finding is similar to previous reports comparing hESC-
derivates and hFib transplant controls [5].
hMNP transplantation altered intracellular signaling pathways
(Fig. 5e,f). 1 day following transplantation, we observed an 86.3%
decrease in phosphorylation of stress-associated protein kinase
(SAPK) in hMNP-transplanted animals (p,0.001). This decrease
was maintained at 4 days post-transplant where hMNP-trans-
planted animals had 59.4% less phosphorylation of SAPK than
controls (p,0.05). At 7 days post-transplant SAPK phosphoryla-
tion increased in hMNP-transplanted animals, however, no
significant difference was observed between groups. Similarly, at
10 days post-transplant the two groups equilibrated and SAPK
phosphorylation was not significantly different. As inflammatory
molecules (eg. TNFa and CD40) and cellular stressors activate
SAPK, it is possible that hMNP-secreted factors inhibited
upstream activators of SAPK thus, attenuating downstream effects
such as apoptosis, immune activation, and inflammation. PCR
array analysis showed that hMNP express 15 fold less CD40 than
hFib, in addition to other downregulated pro-apoptotic and
inflammatory genes. Therefore, it is possible that transplantation
of hMNP alters the immune response following SCI.
Transplantation of hMNPs Improved Functional Outcome
hMNP transplantation enhanced performance on a balance
beam task, which assesses balance and coordination (Fig. 6).
hMNP-transplanted animals performed significantly (p,0.01,
Figure 4. Transplanted hMNPs differentiated following transplantation. Human nuclear antigen-positive cells (a) double stained with Isl-1
(b; red), p75 (c; p75 in red, human nuclei in green), or ChAT (d; ChAT in blue, human nuclei in brown), consistent with a MN lineage of mixed
maturation state. (e) Some human cells in the ventral horns were surrounded by synaptophysin positive processes, suggesting integration with host
tissue (synaptophysin in red, human nuclei in green). (f) Many human cells extended Tuj1 positive processes, and in some animals, ectopic motor
tracts were present in the dorsal and ventral white matter (Tuj1 in red, human nuclei in green). Bar=100 mm for (a) and (b), 50 mm for (c) and (e),
10 mm for (d), 200 mm for (f).
doi:10.1371/journal.pone.0011852.g004
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animals on the balance beam, demonstrating fewer foot faults
(0.760.3 left limb and 0.660.4 right limb in hMNP transplants vs.
1063.5 left limb and 9.263.1 right limb in hFib-transplanted), a
greater average fault distance (13161.7 left limb and 133.960.7
right limb in hMNP transplants vs. 91.268 left limb and
86.7615.2 right limb in hFib-transplanted), and a greater
minimum fault distance (107.6611.5 left limb and 131.962.2
right limb in hMNP transplants vs. 57.3617.5 left limb and
53.2616.8 right limb in hFib-transplanted). hMNP-transplanted
animals began to recover one week earlier than hFib-transplanted
animals on all parameters of the task. Both groups began to
plateau at about 6 weeks post-transplant.
hMNP transplantation enhanced performance on a Montoya
Staircase apparatus, which assesses skilled forelimb reaching.
hMNP-transplanted animals performed significantly (p,0.01)
better than hFib-transplanted animals on number of pellets taken
with the right forelimb at 5 weeks (6.562 vs. 261) and 7 weeks
(862 vs. 361) post-transplant. No differences were observed in left
forelimb function. Similarly, hMNP-transplanted animals per-
formed significantly (p,0.01) better than hFib-transplanted
animals on the success rate (pellets taken/pellets eaten) of the
right forelimb at 5 weeks (1566% vs. 0%) and 7 weeks (2269% vs.
262%), and of the left forelimb at 7 weeks (2767% vs. 563%)
post-transplant. No differences were observed in left forelimb
success rate at 5 weeks post-transplant.
hMNP transplantation did not enhanced performance on a grip
strength task, which assesses distal limb strength. There was no
significant difference (p.0.01) in grip strength of hMNP-
transplanted animals compared to hFib-transplanted animals at
any time point.
Discussion
This study directly assessed the potential of a cell-based
therapeutic to confer neurotrophic benefit to SCI in the absence
of phenotypic benefit. hMNP transplants did not extend processes
through myelinated central and peripheral nervous tissue to
reinnervate distant muscles, thus, their neurotrophic benefit to the
injured spinal cord could be investigated in isolation from the
typical phenotypic benefits conferred by a mixed population
transplant, such as oligodendrocyte-mediated remyelination or
astrocyte-mediated ionic or metabolic homeostasis. These findings
further our understanding of the neurotrophic benefits of hMNP
transplantation, and are the first to demonstrate anatomical and
functional benefit following transplantation of a high purity hMNP
population to adult SCI.
Cell-based therapeutics have proven successful in pre-clinical
SCI models [14] due to their ability to address multiple features of
SCI such as cell loss, demyelination, or homeostatic loss. Several
cell replacement strategies have emerged to treat SCI, including
O-2A progenitors [15,16], Schwann cells [17,18,19], neural stem
cells [8,20], oligodendrocyte progenitors [4,5,21], or bone marrow
stromal cells [22]. The ability of bone marrow stromal cells to
improve the outcome of SCI exemplifies the importance of graft-
derived neurotrophins. In addition, we have recently shown that
human oligodendrocyte progenitor cells secrete a number of
neurotrophic factors and chemokines that benefit the outcome of
SCI, in the absence of graft-derived remyelination [4]. Although
the literature on growth factor secretion by motor neurons is
limited, it has recently been shown that motor neurons not only
respond to neurotrophic cues but also express and secrete growth
factors [23]. Our findings confirm a neurotrophic role for hMNPs,
verifying that they both expressed and secreted neurotrophic
factors that promoted axonal growth and protected neurons from
cell death. Specifically, hMNPs expressed NT-3, NT-4, and NGF,
which, have all been shown to have beneficial effects following SCI
[24,25]. In addition, hMNPs expressed VEGF, a growth factor
that is widely used as an experimental treatment for amyotrophic
lateral sclerosis and promotes motor neuron survival [26]. Our
data demonstrate that hMNP-CM enhanced axonal elongation
and branching of cortical neurites, as evidenced by an increased
number of axon collaterals and dendritic arborizations. Trophic
effects were also observed in axotomized neuronal cultures, where
hMNP-CM enhanced regeneration and sprouting of severed
axons. In addition, hMNP-CM significantly enhanced neuronal
survival in a neurotoxic environment in vitro.
Our transplantation study further confirms that hMNPs have
neurotrophic effects on the surrounding environment. hMNP
transplantation into SCI sites had beneficial effects on injury
pathogenesis, as survival of endogenous neurons and axons was
greater in transplanted animals. These effects may be either direct
or indirect (non-cell autonomous), as trophic support of glial cells
and/or modulation of the glial response may have contributed to
neuronal survival and axonal sparing/regeneration. Although
many of the identified growth factors have been implicated in
neuronal survival, the mechanisms underlying their interaction
with the endogenous environment is yet to be elucidated. It has
been shown that levels of the p75 neurotrophin receptors (NTR)
are upregulated in neurons, while there is a persistent down-
regulation of tyrosine-related kinase receptors (TrkRs) in the
injury vicinity [27]. Although the role of the p75
NTR is highly
debated, it predominantly binds the precursor pro-forms of
neurotrophins and has been implicated in apoptosis [28]. It is
possible that the over-expression of cleaved, mature forms of
growth factors by the transplanted cells is enough to prevent,
inhibit or counteract neurotrophic action at the p75
NTR by
enhancing activation and/or upregulation of TrkRs, enhancing
downstream neurotrophic effects. Moreover, it is possible that
transplantation alters the immune response following SCI,
resulting in less immune-related cell death. Although the mode
of action is not yet determined, our in vitro and in vivo data indicate
that hMNP-derived growth factors enhance neuronal survival in
neurotoxic environments.
Figure 5. Transplanted hMNPs promote histological recovery and alter intracellular signaling pathways. (a) hMNP transplantation
enhanced sprouting of endogenous serotonergic (5-HT) projections. hMNP-transplanted animals consistently contained aberrant projections
throughout the dorsal gray matter (top panels, arrows) and dense innervation of the ventral horns (bottom panels) at 2 mm cranial to the injury site
(b) At 2 mm and 3 mm cranial to the injury epicenter, and 1 mm caudal to the injury epicenter, 5-HT immunoreactivity was significantly greater than
that observed in control animals. At 1 mm cranial to the injury epicenter, and 2 mm and 3 mm caudal to the injury epicenter, 5-HT immunoreactivity
was not significantly different than in control animals. (c) NeuN immunostaining demonstrated that hMNP transplantation enhanced survival of
endogenous (human nuclear antigen-negative) neurons 2 mm cranial to the injury site. (d) Quantification of enhanced neuronal survival in hMNP-
transplanted animals cranial and caudal to the injury site. (e) hMNP transplantation attenuated phosphorylation of stress-associated protein kinase
(SAPK). (f) Densitometric quantification of SAPK normalized to actin controls showed that 1 and 4 days following transplantation, phosphorylation of
SAPK decreased in hMNP-transplanted animals relative to controls; no significant differences were observed between groups at 7 and 10 days.
Bar=200 mm for (a), 100 mm for (c).
doi:10.1371/journal.pone.0011852.g005
Motor Neuron Transplant
PLoS ONE | www.plosone.org 9 July 2010 | Volume 5 | Issue 7 | e11852In addition to enhancing neuronal survival following SCI,
hMNP transplantation enhanced serotonergic innervation around
the transplant site. As different ascending and descending axonal
projections have been shown to respond preferentially to distinct
trophic factors [29], we consider the transplant-induced increase
in serotonergic fiber content in the spinal cord a surrogate marker
Figure 6. Transplanted hMNPs caused functional benefit. hMNP-transplanted animals performed significantly better than controls on the
balance beam, demonstrating fewer foot faults, a greater average fault distance, and an earlier onset of functional recovery as determined by
repeated measures ANOVA (p,0.05); * denotes Student’s t-test p,0.05.
doi:10.1371/journal.pone.0011852.g006
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of neurotrophins, it is likely that they act on numerous ascending
and descending axonal populations.
The changes in SCI pathogenesis following hMNP transplan-
tation correlated with changes in functional recovery. Transplant-
ed animals had an earlier recovery rate of balance and
coordination as well as skilled forelimb movements, suggesting
an immediate neuroprotective effect, preventing neurons from cell
death and axotomized axons from dying back. As transplanted
animals recovered to a greater degree, the cells may have acted as
a sustained vehicle for neurotrophic release, enhancing sprouting/
regeneration of severed descending fibers and possibly restor-
ing connections to endogenous neurons. We did not observe
significant differences in forelimb grip strength, as others have
reported following Schwann cell transplantation into cervical
spinal cord injuries [18]. This discrepancy may be due to the
different injury methods, the different cell type transplanted, the
different number of cells transplanted, or the different placement
of the cells with respect to the lesion epicenter. Nonetheless, the
significant improvement in balance and coordination observed in
our study is comparable to the functional outcomes observed
following transplantation of other cell types into cervical spinal
cord injuries [30,31].
Maturation of transplanted hMNPs was restricted to the ventral
horn. The failure of hMNPs to mature in all other regions of the
spinal cord likely reflected the gliogenic nature of the SCI
environment. Adult spinal cord progenitor cells are restricted to a
glial lineage in situ, generating predominantly oligodendrocyte
precursors [32]. When isolated and expanded in vitro, however,
adult spinal cord progenitor cells are multipotent and differentiate
into neurons, oligodendrocytes, and astrocytes [33]. Nonetheless,
upon transplantation into the spinal cord these multipotent
progenitor cells largely differentiate into glia [6,7] while trans-
plantation into neurogenic regions of the brain results in the
formation of neurons [6]. Proliferating progenitors following SCI
do not express neurogenic basic helix-loop-helix factors or
generate new neurons, suggesting that the mechanisms for
neuronal differentiation are down regulated [34]. Therefore, it is
proposed that the adult spinal cord represents a gliogenic niche.
Furthermore, the gliogenic nature of the adult spinal cord is
upregulated following injury. Neuron-restricted precursor cells
differentiate into mature neuronal subtypes when transplanted
into adult non-injured spinal cord, but fail to differentiate when
transplanted into injured spinal cord [35]. Likewise, NSCs primed
to become cholinergic neurons generate predominantly neurons
and region specific cholinergic neurons when grafted into the non-
injured spinal cord [36], but generate predominantly glial cells
when grafted into the injured spinal cord [37]. Thus, the gliogenic
nature of the injured spinal cord poses a significant challenge to
neuron replacement strategies.
We conclude that the inherent trophic activity of transplanted
hMNPs is sufficient to produce neuronal survival and neurite
branching, which correlates with functional recovery observed in
transplanted injured animals. Efforts to mature transplanted
hMNPs, and enhance axonal projection to target muscles, are
important to maximize the benefits of this cell population.
Materials and Methods
Ethics Statement
All animal work was carried out in accordance with the UCI
Institutional Animal Care and Use Committee (2007–2725).
Animals received appropriate post-surgical care including subcu-
taneous saline, prophylactic Baytril (2.5 mg/kg/d, s.c.; Bayer,
Shawnee Mission, KS), and Buprenorphine (0.025 mg/kg/d, s.c.;
Western Medical Supply, Los Angeles, CA) for three days.
Animals were inspected for weight loss, dehydration, discomfort,
and autophagia, with appropriate veterinary care as needed.
Research involving human participants was approved by the UCI
Institutional Review Board (2008–6467) and the UCI Medical
Center with written informed consent. All work involving human
embryonic stem cells was approved by the UCI Human
Embryonic Stem Cell Research and Oversight Committee
(2007–5645).
hMNP Differentiation
hMNPs were derived from hESC lines hCSC14, hCSC14-CL1
(California Stem Cell, Inc., Irvine, CA) at passages 15–17 and H7
at passages 26–38. hESCs were expanded on Matrigel (BD
Biosciences, San Jose, CA) for 1–3 weeks in EctoBias media
(California Stem Cell, Inc., Irvine, CA) supplemented with 20 ng
bFGF/ml (Millipore, Billerica, MA). Cells were then transferred to
ultra low binding dishes (Corning, NY) and suspended in MN
differentiation media, which consisted of osmolarity adapted
DMEM:F12 mixture (260 mOsm) supplemented with Glutamax,
B27 supplement (Gibco-Invitrogen, Carlsbad, CA), insulin 10 mg/
ml, sodium selenite 1 ng/ml, transferrin 10 mg/ml (Sigma Aldrich,
St. Louis, MO), MgSO4 0.5 mM and bFGF 5 ng/ml (Millipore,
Billerica, MA). Cells were exposed to this media for 5 days,
supplemented with 10 mM retinoic acid (RA; from 20 mM stock
solution in DMSO, Sigma-Aldrich, St. Louis, MO). Cultures were
fed daily for the duration of RA treatment, then every 2 days for
16 subsequent days. At day 21, cell clusters were transferred to
adherent laminin substrate (20 mg/cm
2). At day 28, the condi-
tioned media was collected for in vitro assays, the cells were
prepared for transplantation, or cultured for electrophysiological
assessment. Subsets of cells were plated onto matrigel coated 4-
well chamber slides (Nunc; Fisher Scientific, Pittsburgh, PA) for
immunocytochemical profiling and others were kept for real-time
PCR analysis of neuronal markers.
Electrophysiology
hMNPs were matured for 8 weeks after day 28 on glass
coverslips coated with poly-l-lysine and laminin, in the absence of
growth factors. Cells were current clamped and a 200 msec,
220 pA conditioning pulse followed by a 1 sec 20 pA step was
used for stimulation. The following symmetrical solutions were
used for glutamate-mediated stimulation: external solution (mM):
KCl 145, CaCl2 2, HEPES 10, D-Glucose 5 pH 7.4 NaOH;
pipette solution (mM): KCl 145, CaCl2, HEPES 10, EGTA 10
pH 7.2 KOH. Free Ca
2+ approx 100 nM. Glutamate was applied
at 100 mM, as in [38].
Glutamate-Mediated Toxicity
A stock solution of 100 mM glutamic acid was diluted to either
500 mM or 2000 mM. These dilutions, or 0 mM glutamic acid,
were applied to hMNPs in wells for 24 hours before performing
cell viability assessment. Propidium iodide (PI) and Annexin V
were used to visualize the dead or apoptotic cells on different
plates. A stock staining solution of PI and Hoechst was made by
adding 15 ml Hoechst and 15 ml propidium iodide to 720 ml PBS.
For staining, 10 ml of the PI and Hoechst staining solution was
added to each well for 30 minutes at room temperature. Wells
were imaged immediately after the incubation using the ImageX-
press imager (Molecular Devices). A stock staining solution of
Annexin V and Hoechst was made by adding 40 ml Hoechst and
100 ml Annexin V-A647 to 2000 ml PBS. For staining, 20 ml of the
stock staining solution was added to each well for 30 minutes at
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PFA for 15 minutes. The cells were then washed with PBS three
times for 5 minutes each. The wells were imaged using the
ImageXpress imager (Molecular Devices). PI and Annexin values
were obtained from 8 separate wells, averaged, and presented as a
percentage of Hoechst positive cells.
hMNP Growth Factor Secretion
To investigate the growth factor expression profile of hMNPs,
PCR was used to detect mRNA and western blots were used to
analyze protein expression in both cell lysates and the supernatant.
For PCR analysis, hMNPs were trypsinized, spun at 15006g for 5
minutes, and resuspended in Trizol reagent (Invitrogen, Carlsbad,
CA). RNA extraction was carried out according to the
manufacturers’ protocols. Reverse transcription and PCR were
performed using Retroscript RT kit and GeneAMP RNA PCR kit
(Ambion, Austin, TX) according to manufacturer recommenda-
tions. Samples were run on a 1% agarose gel and water was used
as a no-template negative control. In addition, real-time PCR was
used to quantify differences in expression between hMNPs and
human fibroblasts (hFib, used as a cellular control) using
SuperArray neurotrophin and receptors kit (SABiosciences,
Frederick, MD). Samples were run in triplicate and data is
expressed as fold change versus hFib controls using the delta Ct
method. For western blot analysis, conditioned media was
collected from hMNPs on day 28 of the differentiation protocol.
The media was desalted and concentrated using a YM-10
Centriprep ultrafiltration system (Millipore, Billerica, MA). Pro-
teins were precipitated with a pyrogallol-red molybdate reagent as
previously described [39] and immediately resuspended in loading
buffer. hMNPs were trypsinized, spun at 15006g for 5 minutes,
and the pellet was resuspended in M-PER (Mammalian-Protein
Extraction Reagent; Pierce, Rockland, IL) tissue extraction buffer
containing complete-mini protease inhibitor (Pierce, Rockland,
IL). Cell lysates (25 ug) and proteins extracted from the
supernatant (30 ul of concentrated protein suspension) were
loaded onto a 4–12% bis-tris gel (Bio-Rad, Hercules, CA) with a
multi-mark molecular weight ladder (Invitrogen, Carlsbad, CA).
Proteins were probed with antibodies against NT-3, NT-4, NGF
(1:1000, Millipore, Billerica, MA), and VEGF (1:2000, AbCam,
Cambridge, MA).
Primary Cortical Cultures
Mixed primary cortical cultures were prepared from postnatal
day 1 Sprague-Dawley rats for neurite outgrowth and from
embryonic day 18 rat pups for survival and regeneration studies,
with and without hMNP-conditioned media (CM) or MN
differentiation media (without conditioning). The cortex was
mechanically dissociated, trypsinized, and spun at 15006g for 5
minutes. The pellet was resuspended in Neurobasal media
(Invitrogen, Carlsbad, CA). 40,000 cells were plated onto poly-l-
lysine coated chamber slides for neurite outgrowth and survival
studies and 10,000 cells were plated into the somal side of
microfluidic culture platforms coated with poly-l-lysine at 1 mg/
ml for neurite regeneration [12]. After seeding, the chamber slides
and the microfluidic chambers were fed for the next 2 days with
Neurobasal media supplemented with 10 ng/ml FGF until
neuronal attachment.
Neurite Outgrowth Assay
To determine whether hMNP-CM had neurotrophic effects on
neurite outgrowth, media was conditioned for 48 hours in the
presence of hMNPs and removed for presentation to cortical
neurons. Primary cortical neurons were fed with either MN
differentiation media or hMNP-CM diluted 1:1 with MN
differentiation media (n=4/group). For antibody inhibition
experiments, neutralizing antibodies against candidate growth
factors were added to the culture media at their ND50. Antibodies
against neurotrophin 3 (NT 3), neurotrophin 4 (NT4), nerve
growth factor (NGF) (Millipore, Billerica, MA), vascular endothe-
lial growth factor (VEGF) (AbCam; Cambridge, MA), and glial
derived neurotrophic factor (GDNF) (R&D Systems; Minneapolis,
MN) were added to determine whether inhibition of these growth
factors would attenuate neurite elongation (n=4/antibody/
group). Primary neurons were fixed on day 7 with 4% par-
aformaldehyde, immunostained using an antibody against Tuj1
(b-3 tubulin subunit, Covance, Princeton, NJ) and counterstained
with Hoechst 33258 (Invitrogen Carlsbad, CA). Twenty pictures at
4006magnification were digitally recorded and used to quantify
mean neurite length, the number and types of neurites, and the
number of surviving cells. Neurite length was measured by tracing
two Tuj1 positive axons per field from the cell body to the tip of
the axon using NIH ImageJ software (ImageJ software U. S.
National Institutes of Health, Bethesda, Maryland). Neurite length
was averaged for each group and expressed in micrometers.
Neurite Regeneration Assay
To determine whether hMNP-CM had neurotrophic effects on
neurite regeneration, media was conditioned for 48 hours in the
presence of hMNPs and removed for presentation to axotomized
cortical neurons. Primary cortical neurons were plated onto a
microfluidic culture platform that isolates axons from somata [12].
After 7 days of axon growth and maturation, the media and axons
were aspirated using a fire-polished glass pipette. Axotomy was
confirmed under a microscope and the media was replaced with
either hMNP-CM or MN differentiation media (n=5/group).
Axons were allowed to regenerate for 5 days, the cultures were
fixed in 4% paraformaldehyde and stained for neurofilament
(Millipore, Billerica, MA) and MAP-2 (Sigma-Aldrich, St. Louis,
MO). 4006images were taken along the length of the neurite side
of the platform using a confocal microscope, inverted to grey scale
images of the same threshold, and optical density was determined
as mean grey value in pixels using Image J software (U. S. National
Institutes of Health, Bethesda, Maryland, USA) and averaged
across groups.
Cytotoxicity Assay
Following CNS injury, activated microglia release toxic
substances such as nitric oxide, tumor necrosis factor alpha, and
interleukin-1b that play an essential role in neuroinflammation
and neurodegeneration [40,41]. To investigate whether hMNP-
CM can protect cortical neurons from the neurotoxic effects of
activated microglia, BV-2 microglia were cultured and the
conditioned media was collected after 24 hours from control
microglia and microglia activated with 100 ng/ml of lipopolysac-
charide (LPS; kind gift from Dr. Frank LaFerla’s Lab). Microglial
conditioned media (MG-CM or LPS-MG CM) was then filtered
and used for neuronal survival assays in the presence of hMNP-
CM or MN differentiation media (n=4/group). After neuronal
attachment, the cultures were treated with either MG-CM or LPS-
MG CM diluted 1:1 with hMNP-CM or MN differentiation
media. After 3 days of treatment, cultures were fixed in 4%
paraformaldehyde, immunostained for MAP-2 (Sigma-Aldrich, St.
Louis, MO) and 20 digital images of each chamber well were
captured at 4006magnification. The number of positive neurons
was quantified using ImageJ software and the mean number of
neurons for each group was recalculated as cells/cm
2.
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Muscle fragments from day 1–5 rats or adult human biopsies
were minced and dissociated using 2 mg/ml Collagenase IV
(Invitrogen, Carlsbad, CA) and transferred in a 25 cm
2 cell culture
flask coated with Matrigel 1:30 (BD Biosciences, San Jose, CA).
Cultures were fed every second day with MyoBlast media
(California Stem Cell Inc., Irvine, CA) supplemented with
10 ng/ml FGF2 (Millipore, Billerica, MA).
hMNPs and myoblasts were transferred to separate chambers of
microfluidic culture platforms connected by 5–20 mm micro-
channels [12]. The neural chamber was seeded with hMNPs and
cultured for 2 weeks in serum-free MN differentiation media
supplemented with 2 ng/ml FGF2. The muscle chamber was then
seeded with myoblasts and fed with MyoBlast media (California
Stem Cell Inc., Irvine, CA) for two days followed by MyoBlast
media supplemented with 10% FBS. After 2–3 days, a video
camera attached to the microscope was used to record the
muscular activity.
Immunocytochemical Labeling
Cultures were fixed, blocked, and exposed to the primary
antibodies anti-PAX6 1:200, anti-NG2 1:200, anti-serotonin
1:200, anti-Olig1/2 1:200, anti -Isl1 1:200, anti-PDGFR-2
1:100, anti-Tuj1 1:1000, anti-human nuclear antigen 1:200,
anti-synaptophysin 1:100, anti-SMI-32 1:1000, anti-ChAT 1:100
(Millipore, Billerica, MA) and anti-HB9 1:100 (MNR2 Ab from
DSHB Developmental Studies Hybridoma Bank) at 4uC over-
night. Primary antibody application was followed by fluorescent
secondary antibodies (CY3 or Alexafluor-488 conjugated; Invitro-
gen, Carlsbad, CA).
To immunocytochemically assess MN functionality; Co
2+
labeling was performed [42,43]. Cultures were exposed to
100 mM kainite plus 2.5 mM CoCl2 in uptake buffer (139 mM
sucrose, 57.5 mM NaCl, 5 mM KCl, 2 mM MgCl2,2 m M
CaCl2, 12 mM glucose, 10 mM Hepes) for 10 minutes at room
temperature, washed in uptake buffer plus 2 mM EDTA and
incubated in 0.05% (NH4)2S for 5 minutes. After two washes in
PBS, cells were fixed in 4% paraformaldehyde for 1 hour. A
modified Timm’s stain procedure was employed at room
temperature [44,45]. The cultures were incubated in the dark in
a solution consisting of 1 part solution A (0.1 M AgNO3), 20 parts
of solution B (2% hydroquinone and 5% citric acid in water), and
100 parts of solution C (20% gum arabic, in water).
For neurite and neuronal cell body identification, fixed cortical
neuron cultures were blocked, and then exposed to primary
antibodies (anti-neurofilament 70; 1:500 (Millipore, Billerica, MA),
anti-MAP-2; 1:1000 (Sigma, St. Louis, MO) at 4uC overnight,
followed by fluorescent secondary antibodies (Alexafluor – 488 or
594 conjugated; Invitrogen, Carlsbad, CA).
For neuromuscular junction identification, myoblast and MN
co-cultures were fixed with 4% paraformaldehyde for 10 minutes,
and then exposed to a-bungarotoxin, Alexa Fluor 594 conjugate
(Invitrogen, Carlsbad, CA) for 1 hour.
Spinal Cord Injury Model
Adult, female Sprague-Dawley rats (Charles River Laboratories,
SanDiego,CA) wereanesthetizedusingKetamine(100 mg/kg)and
Xylazine (10 mg/kg, i.p.: Western Medical Supply, Los Angeles,
CA) and underwent a C5–C6 laminectomy. A 200 kD bilateral
contusion injury was delivered using an Infinite Horizons Impactor
(Precision Systems and Instruments, Lexington, KY). Seven days
later, the animals werere-anesthetized and the laminectomysitewas
re-exposed. The animals were secured to a stereotactic apparatus,
and a total of 100,000 hMNPs, 500,000 hMNPs, human fibroblasts
(hFib) (n=15/group, 25,000 cell/ml) or volume equivalent of
vehicle (n=15) were transplanted bilaterally into the ventral horn
(0.5 mm from the midline, 1.2 mm from the dorsal surface) rostral
and caudal to the injury site using a 33 G needle attached to a
Hamilton syringe. One day prior to transplant and for the duration
of the experiment, animals received cyclosporine A (20 mg/kg/d,
s.c.; Bedford Laboratories, Bedford, OH).
Animals were acclimated 10 minutes everyday for one week,
then trained on the balance beam (Lafayette Instruments,
Lafayette, IN) for 2 weeks prior to injury. Following injury, the
animals were tested two times a week. For testing, animals
traversed a 135 cm, tapered balance beam 5.5 cm wide at the start
and 1.5 cm wide at the finish. The beam is equipped with a 2 cm
wide ledge that is attached 2 cm below the surface of the beam to
provide support for injured animals [46]. The animals ran 5 trials
with a 1minute break in between each trial and the number of foot
faults and foot fault distance was recorded for the left and right
forelimb by two independent observers. Animals that could not
perform the task following SCI received the maximum number of
foot faults/trial (5) and a zero as their fault distance.
Grip strength assessments were performed on animals trained to
the task everyday for 3 weeks prior to SCI. Baseline data was
collected on the last four days of training before SCI. Animals
were tested once a week for 6 weeks and every other week
thereafter. The testing period consisted of 5 trials where the
animals were presented to the grip strength meter bar (TSE-
Systems and distributed by SciPro, Inc.) while one forelimb was
restrained by the experimenter. The force with which the animals’
grabbed the bar was recorded for each trial and for each forelimb,
averaged, and averaged across groups.
Skilled reaching was assessed using the Montoya Staircase
apparatus modified to increase the sensitivity using color-coded
pellets [47]. The animals were trained for 3 weeks where they were
placed in the plexiglass staircase for fifteen minutes and allowed to
grab freely at the different color pellets baited on each stair.
Baseline data was collected 3 days prior to injury and post-injury
data collection was performed twice a week for fifteen minute
testing sessions and averaged. The number of pellets taken and the
number of pellets eaten were recorded and used to determine the
success rate.
Smn
2/2;SMND7
+/+;SMN2
+/+ Model
Smn
2/2;SMND7
+/+;SMN2
+/+ mice at post-natal day 1 were
secured to a stereotactic apparatus and a total of 20,000 hMNPs
(n=15/group, 10,000 cell/ml) or volume equivalent of vehicle
(n=15) were transplanted bilaterally within the 6
th thoracic
segment using a 33 G needle attached to a Hamilton syringe.
Immunohistochemical Labeling
For the SCI model, a small cohort of spinal cord injured animals
in each group (n=4) received intramuscular injections of the
retrograde tracer, cholera toxin B (1 mg/ml CTB; Invitrogen,
Carlsbad, CA), to label innervating motor axons four days prior to
sacrifice. The animals received 4-1 ul injections into the bicep
muscle and 8-1 ul injections into the triceps muscles using a 10 ul
Hamilton syringe. 2 or 3 months post-transplant, the animals were
sacrificed by aortic perfusion with 4% paraformaldehyde and the
tissue was cryopreserved for sectioning. Tissue was immunolabeled
for neuronal nuclei (NeuN; 1:200, Millipore, Billerica, MA),
oligodendroglial cells (OSP; 1:1000, AbCam, Cambridge, MA),
astrocytes (GFAP; 1:1000, DAKO, Carpenteria, CA), interneu-
rons (GAD65/67; 1:1000, AbCam, Cambridge, MA), neuronal
processes (Tuj1; 1:1000, Covance, Princeton, NJ), retrograde
transport (CTB, Invitrogen, Carlsbad, CA) or the motor neuron
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ChAT (1:100; Millipore, Billerica, CA) using immunofluorescence
or the ABC method with DAB+nickel as a substrate.
NeuN positive neurons were quantified in sections 200 mm
apart at 2 mm rostral and 2 mm caudal to the injury epicenter.
Serial sections were labeled with human nuclear antigen to ensure
no human cells were included in the analysis. Images were
captured at 4006 magnification from 4 fixed regions within the
grey matter representing .30% of the total grey matter (n=5
animals/group). The number of cells in each area was quantified
using ImageJ software, averaged for each animal, and recalculated
as neurons per mm
2. To investigate whether transplantation of
hMNPs enhanced axonal sprouting of descending and ascending
tracts, we visualized descending serotonergic projections (5-HT,
1:200; AbCam, Cambridge, MA). Digital images were captured of
both dorsal and ventral horns at 2006 magnification (for 5-HT)
and dorsal horns only (for CGRP) from tissue sections spaced
200 um apart (n=5 animals/group). The area quantified
represented .50% of the total gray matter area. All pictures
were taken at the same exposure, imported using ImageJ software
(U. S. National Institutes of Health, Bethesda, Maryland) and
inverted to grayscale images of the same threshold. The density of
staining was determined by multiplying the grey value in pixels by
the area measured and was expressed in arbitrary units (au).
Statistical analysis was performed using a Student’s t-test.
Morphometric analysis of spinal cord size was conducted by
tracing three tissue sections 100 mm apart 1 mm cranial and 1 mm
caudal to the injury epicenter, using Olympus MicroSuite B3SV
software; the measurements within corresponding blocks from
animals within a group were then averaged. All cystic enlarge-
ments were subtracted from the total area.
For the Smn
2/2;SMND7
+/+;SMN2
+/+ model, mice were sacri-
ficed 7 days post-transplantation via trans-cardiac perfusion with
4% paraformaldehyde (Smn
2/2; SMND7
+/+;SMN2
+/+ mice typical-
ly expire within 14 days of birth). The tissue was cryopreserved in
27% sucrose and the cords were sectioned into 1 mm blocks and
embedded in OCT compound. Tissue was cryosectioned at 20 mm
and mounted onto gelatin coated slides. Tissue sections were
blocked with 10% NDS in PBS and permeabilized with 0.1%
Triton X-100. To determine the fate of the transplanted hMNPs,
sections were double-labeled with primary antibodies Ku80 (1:300;
Abcam) and Islet-1 (1:200; Abcam) overnight at room temperature.
Donkey anti-rabbit conjugated with biotin (1:250; Invitrogen),
Streptavidin 594 (1:250; Invitrogen), and Streptavidin 488 (1:250;
Invitrogen) or goat anti-rabbit Alexa Fluor 488 (1:250; Invitrogen)
was used for 2 hours at room temperature as secondary antibodies.
Transplant-Induced Spinal Cord Changes
To investigate the signaling pathways that were altered following
hMNP transplantation, 200 kD bilateral contusion injuries were
induced as above and 100,000 hMNPs (n=16) or vehicle (n=16)
were injected intraspinally seven days post-injury. All animals were
injected with 20 mg/kg/day of CSA. 4 animals from each group
were sacrificed at 1, 4, 7, and 10 days post-transplant by
decapitation (n=4/group/timepoint). The spinal cords were
quickly removed, flash frozen in liquid nitrogen, and stored on
ice in 95% ethanol. Protein was extracted using RIPA buffer
(Sigma-Aldrich, St. Louis, MO) supplemented with protein and
phosphatase inhibitors at 26concentration (Pierce, Rockland, IL).
The tissue was homogenized and the extract was spun at
13000 rpm for 15 minutes. The supernatant was collected and
protein concentrations were determined using BCA assay (Pierce,
Rockland, IL). Proteins were loaded onto a 4–12% Bis-Tris gel
(Bio-Rad, Hercules, CA) at a concentration of 10 ug. Kaleidoscope
molecular weight markers were used as a standard (Bio-Rad,
Hercules, CA). Nitrocellulose blots were probed for MAP kinases
(Cell Signaling, Danvers, MA) at a dilution of 1:1000 according to
manufacturer’s protocol. Secondary antibodies conjugated to HRP
(Cell Signaling, Danvers, MA) were used at a concentration of
1:2000 or 1:5000 and Super Signal West Pico chemiluminescent
substrate (Pierce, Rockland, IL) was used for detection. Densitom-
etry was performed using ImageJ software (U. S. National Institutes
of Health, Bethesda, Maryland) and data is expressed relative to
actin control. Significance was determined using a Student’s t-test.
Supporting Information
Figure S1 (a) Real-time PCR revealed a 10-fold increase in NT-
3, a 23-fold increase in NT-4, an 18-fold increase in VEGF, a 3.5-
fold increase in CNTF, a 6-fold increase in IL10, a 121-fold
increase in NRG4 (neuregulin 4), and a 275-fold increase in NPY
(neuropeptide Y) when compared to controls. There was a 5-fold
decrease in NGF expression in hMNP when compared to hFibs (b)
Western blot analysis confirming that hMNP express and secerete
NT-3, NT-4, NGF, and VEGF.
Found at: doi:10.1371/journal.pone.0011852.s001 (7.37 MB TIF)
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